# Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

> **NCT00984464** · PHASE2 · COMPLETED · sponsor: **Oncolytics Biotech** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** REOLYSIN
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00984464
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-02
- **Final completion:** 2014-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00984464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00984464, "Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00984464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*